# Cassava Sciences (SAVA)

Gilead Sciences Receives sNDA from the FDA for Remdesivir for Pediatric Patients with COVID-19 Gilead Sciences ( GILD ) announced that the U.S. Food and Drug Administration ( FDA ) has approved a supp...

Prohost Biotech

Feb 28, 2025

Gilead Sciences: Remdesivir is the First and Only Approved Treatment for Pediatric Patients with COVID-19. See Also: Cassava Sciences

Vertex Pharmaceuticals Statistically Significant Results From Vertex VX-548 for Acute Pain Vertex Pharmaceuticals ( VRTX ) announced positive results from two Phase 2 proof-of-concept ( POC ) studies...

Prohost Biotech

Apr 26, 2022

News From Vertex and Cassava: Two Prohost Portfolio Selected Biotech Firms

Cassava Sciences, Vertex Pharmaceuticals and Gilead Sciences All Have Good News Cassava Sciences & Alzheimer's Disease Cassava Sciences ( SAVA ) announced the initiation of a second Phase 3 trial of s...

Prohost Biotech

Mar 31, 2022

Let's Talk About 3 Firms with Important News: Cassava Sciences, Vertex Pharmaceuticals and Gilead Sciences

Prohost Biotech

Nov 19, 2021

0

Cassava Science: Journal of Neuroscience Review Shows No Evidence of Data Manipulation Cassava Sciences (SAVA) has been informed by the Journal of Neuroscience that there is no evidence of data manipu...

No Evidence of Data Manipulation in Technical Paper Foundational to Cassava Sciences Lead Drug Candidate

Cassava Sciences Announces Top-Line Clinical Data for Simulfilam Cassava Sciences Press Release Today Cassava Sciences ( SAVA ) announced top-line clinical data today from a pre-planned interim analys...

Prohost Biotech

Nov 4, 2021

Encouraging News from Cassava Sciences

The Comprehensive Prohost Letter Issues The Comprehensive Prohost Letter Issues will constitute a chain of 7 issues. Today’s issue will include the following: Pinpointing and selecting the biotech fir...

Prohost Biotech

Sep 22, 2021

Comprehensive Prohost Letter Issues

Prohost Biotech

Sep 19, 2021

5

Cassava Sciences Released a Statement Cassava Sciences, Inc. (SAVA) - a biotechnology company focused on Alzheimer’s disease, today released a statement regarding plasma p-tau analysis from a previou...

Cassava Statement Regarding Plasma p-tau Analysis from a Previously Disclosed Phase 2b Study in Alzheimer's Patients

Cassava Sciences Responds to Misleading Posts Cassava Sciences ( SAVA ) today issued a response to claims that were posted online yesterday after market hours. Cassava Sciences believes the claims mad...

Prohost Biotech

Aug 27, 2021

Cassava Sciences Issued a Response to Claims Posted After Market Yesterday. See Also: Cassava Sciences Good News

Prohost Letter #446 A Reevaluation of Prohost Biotech’s Picked Firms We have already pinpointed some of the devastating and life-threatening diseases that have yet to find treatment. Prohost’s plans a...

Prohost Biotech

Aug 25, 2021

A Reevaluation of Prohost Biotech's Picked Firms

Sanofi Will Acquire Translate Bio Sanofi ( SNY ) will acquire all the outstanding shares of Translate Bio ( TBIO ) for $38.00 per share in cash, which represents a total equity value of approximatel...

Prohost Biotech

Aug 9, 2021

Sanofi to Acquire Translate Bio, Advancing mRNA Technology. See Also: Cassava Science Q2 Financial Results

Cassava Sciences There is no doubt in our minds that Cassava Sciences’ ( SAVA ) product simufilam will play a major role in the treatment of Alzheimer’s disease. We have no doubt that simufilam has im...

Prohost Biotech

Aug 3, 2021

AstraZeneca: Big Step Towards Improving the Lives of SLE Patients and More on Cassava Sciences

Cassava Sciences Inc Following Cassava Sciences Inc successful and promising presentations, all the titles of the news and articles written by fair professionals have been as follows: “Cassava Science...

Prohost Biotech

Aug 2, 2021

Cassava Sciences Good News and an Unwarranted Sell-Off. A New Drug Approval for Bristol-Myers Squibb and ImmunoGen Quarterly Results

Prohost Biotech

Jul 30, 2021

1

Cassava Sciences Inc Press Release Related to Positive Biomarker Data Cassava Sciences Inc (SAVA) announced today, in a press release, positive biomarker data from an open-label study of simufilam, t...

Cassava Sciences Inc: Today's Press Releases

Prohost Biotech

Jul 29, 2021

8m

1

Cassava Sciences: Positive Clinical Data with SavaDX Cassava Sciences (SAVA) today announced positive clinical data with SavaDx, an investigational diagnostic/biomarker to detect Alzheimer’s disease w...

Cassava Sciences Announces Positive Data with SavaDx from a Randomized Controlled Phase 2b Study of Simufilam

bluebird bio Receives EC Approval for bluebird bio ( BLUE ) announced that the European Commission ( EC ) has granted marketing authorization of SKYSONA™ (elivaldogene autotemcel, Lenti-D™) one-tim...

Prohost Biotech

Jul 26, 2021

bluebird bio Receives Approval for its Gene Therapy SKYSONA™ for Young People with Early CALD Without a Matched Sibling Donor

Cassava Sciences Soared Cassava Sciences ( SAVA ) stock soared today. The firm announced that it will present two new clinical datasets for its product candidates at the 2021 Alzheimer’s Association I...

Prohost Biotech

Jul 22, 2021

Cassava Sciences Stock Soared. See Also: The Resurrection of Sunesis Pharmaceuticals

Prohost Portfolio PLUS #7 Companies Behind The Biotechnology Revolution Without these firms, basic science discoveries in the universities and the academic institutions and by the firms themselves wou...

Prohost Biotech

Jul 21, 2021

Companies Behind the Biotechnology Revolution

Biogen Product Adulelm Approved for Alzheimer's Disease The latest news regarding Alzheimer’s disease is that of the FDA’s approval of Biogen Inc's ( BIIB ) Alzheimer disease product Adulelm (aducanum...

Prohost Biotech

Jul 12, 2021

The FDA Approval of Biogen's Alzheimer's Disease Drug and How Cassava Sciences Alzheimer's Disease Drug Differs

Annovis Bio Inc and Neurodegenerative Diseases Annovis Bio Inc ( ANVS ) , a clinical-stage drug platform company. This firm's focus is the treatment of neurodegenerative diseases. Annovis Bio Inc anno...

Prohost Biotech

Jun 12, 2021

Annovis Bio Inc: Very Encouraging Trial Results in Neurodegenerative Diseases

Prohost Biotech

May 21, 2021